Expert Interview
A Second Opinion: Checking in with a prescriber of Amylyx's Relyvrio for the slowing of ALS progression.
Ticker(s): AMLXInstitution: George Washington University
- Assistant professor of Neurology and Director of the ALS Clinic at The George Washington University.
- Currently manages over 100 patients with ALS, and has prescribed Relyvrio to every patient.
- PI on the HEALEY platform trials with a research focus on neuromuscular disorders and ALS.
Roughly how many ALS patients have you prescribed Relyvrio to?
Added By: max_adminHow does Relyvrio compare to other treatment options available?
Added By: max_adminOverall what has the patient satisfaction been with this product?
Added By: max_adminIt’d be helpful if you could walk us through
the typical ALS patient journey as it pertains to therapeutic interventions.
How you think about the therapies that you have at your disposal with riluzole,
edaravone, and relyvrio? What determines you prescribing one over another or
several agents in combination?
When did you begin prescribing relyvrio and what
has your experience with the drug looked like so far? Have you noticed any
significant changes in access / your utilization trends since you first started
using it?
What about your colleagues, do you think they’re
typically utilizing relyvrio in a similar way?
Added By: max_admin
Added By: max_admin
Amylyx has phase 3 data upcoming next year. What
are your expectations for the trial and how do you see the outcome impacting
your utilization going forward?
Any difference in insurance coverage between relyvrio and raticava?
Added By: max_adminAre you familiar with the TUDCA-ALS Italian study?
Added By: max_adminAre you familiar with masitinib?
Added By: max_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
